Elijah Behr

Elijah Behr is a Professor of Cardiovascular Medicine, Consultant Cardiologist, and Electrophysiologist specializing in sudden cardiac death, genetics, and genomics. His research focuses on arrhythmia syndromes, inherited cardiac conditions, and genetic testing integration into clinical practice. Behr is actively involved in evaluating novel diagnostic methods like pharmacological provocation testing and synthetic electrocardiogram analysis for conditions such as Brugada syndrome.

His work spans clinical trials comparing implantable defibrillator therapies (subcutaneous vs transvenous), exercise tolerance in hypertrophic cardiomyopathy, and molecular mechanisms underlying cardiomyopathies. He has contributed to consensus guidelines on genetic testing for cardiomyopathies and device therapy optimization. Behr’s studies also address population-specific genetic variants (e.g., SCN5A in Thailand) and outcomes in rare cardiac diseases identified via large-scale genomic projects like the 100,000 Genomes Project.

Key research themes include arrhythmia risk stratification, sex-based differences in device complications, and the role of genetics in sudden cardiac death. His multidisciplinary approach combines clinical cardiology with advanced genomic techniques to improve diagnostic accuracy and patient care in inherited heart conditions.

Behr’s academic contributions are further reflected in his leadership in international trials like TETRIS and PRAETORIAN-XL, which investigate arrhythmia management strategies. He advocates for comprehensive molecular autopsy protocols to identify genetic causes of sudden death and improve familial screening.